Építés alatt – nem éles oldal
Belépés
Leállítva3. fázis

Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial

A legfontosabb adatok

Ki végzi
Emory University
Hol
Atlanta (Egyesült Államok)Mind a 4 helyszín megnézése
Azonosító
Állapot
Leállítva
Fázis
3. fázis
Résztvevők
5 fő vett részt
Kezdés
2024. márc. 8.
Befejezés
2024. jún. 24.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Cetirizine
  • Famotidine
  • Cetirizine Placebo
  • Famotidine Placebo
A regiszteradat frissítve
2025. július 17.
Miért állt le
Study was terminated due to lack of funding.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 24 feltétel megnézéseKevesebb

Ki vehet részt

  • Adults ≥18 years of age with a history of a SARS-CoV-2 PCR positive test and/or medical records from a healthcare provider that coincides with the diagnosis of long-COVID
  • New or worsened symptoms since the onset of COVID-19 that are persistent at the time of enrollment and have lasted for ≥ 12 weeks (including at least one of the following: fatigue, post-exertional malaise (PEM), headache, brain fog, sleep disturbance, dysautonomia
  • Confirmation of negative urine or serum human chorionic gonadotropin (HCG) (pregnancy) test in women of childbearing potential
  • Willing to use appropriate contraceptives for female and male subjects for the duration of the study
  • Has an address (for mailing of study drug) in the state of Georgia
  • Able to swallow capsules
  • Has reliable access to a mobile phone, tablet, laptop, or desktop computer capable of connecting to the internet via Wi-Fi or a data plan
  • Available lab work (CBC and CMP) after the onset of long COVID symptoms
  • Willing and able to comply with scheduled visits, treatment plan, and other study procedures including receiving either intervention or placebo
  • Willing to not take any of the study medications while enrolled in the study except for essential needs as prescribed by a healthcare provider

Ki nem vehet részt

  • Currently immunocompromised from the following: solid organ transplant, bone marrow transplant (BMT), high dose steroids (>20mg prednisone per day), immune modulators, or chemotherapy
  • Currently taking opioid analgesics, undergoing treatment for opioid addiction, or taking any other prohibited concomitant medication
  • Known sensitivity or adverse reaction to H1 or H2 receptor antagonists, or medication components
  • Currently receiving other therapies to treat COVID-19 or Long COVID symptoms, e.g., convalescent plasma, remdesivir, Paxlovid
  • No post-acute COVID-19 symptoms (PASC) symptoms at the time of enrollment or PASC symptoms present <12 weeks at the time of enrollment
  • Actively enrolled in another Long COVID/PASC interventional trial or participation in another interventional clinical trial in the last 30 days or planned during the trial period
  • Other medical conditions occurring after the onset of COVID-19 that can otherwise account for PASC-type symptoms
  • Opioid dependence or withdrawal syndrome
  • Unstable medical comorbidities (e.g., decompensated cirrhosis, stage III-IV chronic kidney disease, New York Heart Association (NYHA) class III congestive heart failure), per the patient report, telemedicine physical exam, baseline laboratory values (hematology and extended chemistry panels) and/or medical records
  • Inability to provide own informed consent
  • Currently Hospitalized
  • For women of childbearing potential (WOCBP), currently pregnant or plans to become pregnant during the study period; for males with partners of childbearing potential (OCBP), plans to become pregnant during the study period
  • Suspected or confirmed pregnancy or breastfeeding
  • Participants already on H1 or H2 receptor antagonists within three (3) months of randomization

Helyszínek itt: Egyesült Államok

  • Emory HospitalAtlanta, Egyesült Államok
  • Emory University Hospital MidtownAtlanta, Egyesült Államok
  • Grady Health SystemAtlanta, Egyesült Államok
  • Metro-AtlantaAtlanta, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The primary objective of this study is to assess the feasibility and acceptability of methods and procedures to be employed in a larger scale decentralized platform adaptive randomized clinical trial in patients with a history of a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Polymerase Chain Reaction (PCR) positive test and/or medical records from a healthcare provider that coincides with the diagnosis of long-COVID.

A vizsgálat 2 csoportja

  • HRA Treatment ArmA vizsgált kezelés

    Participants randomized to Treatment Arm will receive dual histamine receptor antagonists: famotidine and cetirizine daily.

    Kezelés: Cetirizine és Famotidine

  • Placebo ArmPlacebo, összehasonlításként

    The compounding study pharmacy will provide placebo capsules to the patients randomized to Placebo. These capsules are manufactured to match each treatment drug for oral administration.

    Kezelés: Cetirizine Placebo és Famotidine Placebo

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Feasibility Assessment of a Decentralized Platform Adaptive Double-Blind, Randomized Controlled Trial Investigating Repurposed Drugs in the Treatment of Post-Acute Sequelae of Coronavirus-19 (PASC)
A regiszteradat frissítve
2025. július 17.